Labcorp (NYSE: LH) announced the launch of its Fentanyl Urine Visual Test, which the company describes as the first FDA-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in 10 minutes and is designed for use in emergency departments, hospitals and clinics.

The test detects norfentanyl, the primary fentanyl metabolite, which can remain present in urine up to 48 hours after initial exposure. This provides a longer detection window than fentanyl itself, which may clear within hours. The test is FDA-cleared for use by qualified professionals in Clinical Laboratory Improvement Amendments (CLIA)-certified settings.

According to Labcorp data, approximately 4% of pre-employment screenings tested positive for fentanyl between 2024 and 2025, and nearly 10% of patients receiving opioid use disorder treatment tested positive. The Association for Diagnostics and Laboratory Medicine has issued guidance highlighting the importance of reliable screening tools in emergency care as synthetic opioids become more prevalent.

"When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "The Labcorp Fentanyl Urine Visual Test delivers results in minutes, helping teams respond quickly and confidently in emergency departments, hospitals and clinics."

The test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics. Throughout 2026, product names, packaging and resources will transition from MEDTOX Diagnostics to Labcorp Point of Care. Results are intended for preliminary rapid screening purposes and should be confirmed using appropriate laboratory methods, according to standard practice for rapid testing.